Valuation : Protalix BioTherapeutics, Inc.

Market Cap 205M 177M 166M 151M 284M 19.52B 286M 1.96B 766M 9.87B 768M 752M 32.75B P/E 2026 *
13.4x
P/E 2027 * 46.2x
Enterprise Value 205M 177M 166M 151M 284M 19.52B 286M 1.96B 766M 9.87B 768M 752M 32.75B EV / Sales 2026 *
2.56x
EV / Sales 2027 * 3x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week+6.72%
Current month+7.17%
1 month+5.83%
3 months+19.81%
6 months-11.81%
Current year+41.11%
1 week 2.34
Extreme 2.34
2.65
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.52
Extreme 1.5201
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 2019-06-29
Director of Finance/CFO 57 2025-08-23
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Director/Board Member 73 2008-06-30
Director/Board Member 83 2014-10-31
Director/Board Member 59 2019-06-29
Date Insider Type Main position Quantity % Market Cap.
12/19/25 Buy

Chief Executive Officer

56,000 0.0696%
11/18/25 Sell

Director

168 0.0002%
9/3/25 Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%+6.72%+58.75%+31.61% 210M
-0.13%-5.61%+59.99%+112.16% 1,048B
+0.85%+0.25%+51.61%+61.23% 640B
-1.03%-2.43%+22.79%+74.16% 456B
-1.46%-3.52%+36.60%+38.39% 362B
-0.72%-2.06%+21.34%+37.92% 295B
-1.19%-0.98%+0.79%+12.29% 255B
-1.05%-0.30%+50.16%+68.66% 236B
+0.08%-0.22%-17.16%-53.76% 204B
-2.14%+1.56%+27.88%+89.54% 185B
Average -0.82%-0.10%+31.28%+47.22% 368.18B
Weighted average by Cap. -0.31%-1.92%+37.92%+65.36%

Financials

2026 *2027 *
Net sales 79.8M 68.89M 64.58M 58.96M 111M 7.61B 111M 766M 299M 3.85B 300M 293M 12.77B 68.19M 58.87M 55.19M 50.39M 94.8M 6.5B 95.26M 654M 255M 3.29B 256M 250M 10.91B
Net income 15.38M 13.27M 12.44M 11.36M 21.37M 1.47B 21.48M 148M 57.58M 742M 57.72M 56.46M 2.46B 4.46M 3.85M 3.61M 3.3M 6.2M 426M 6.23M 42.82M 16.71M 215M 16.76M 16.39M 714M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
26-08-28 US$2.540 -2.68% 489,651
26-08-27 US$2.610 +5.24% 1,293,530
26-08-26 US$2.480 +3.33% 1,023,782
26-08-25 US$2.400 -0.41% 497,742
26-08-24 US$2.410 +1.26% 409,933
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.610USD
Average target price
11.00USD
Spread / Average Target
+321.46%

Quarterly revenue - Rate of surprise